- Home
- AENT vs BNTC Comparison
AENT vs BNTC Comparison
Compare AENT & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- BNTC
- Stock Information
- Founded
- AENT 1990
- BNTC 1995
- Country
- AENT United States
- BNTC United States
- Employees
- AENT N/A
- BNTC N/A
- Industry
- AENT Durable Goods
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- BNTC Health Care
- Exchange
- AENT Nasdaq
- BNTC Nasdaq
- Market Cap
- AENT 290.3M
- BNTC 339.8M
- IPO Year
- AENT N/A
- BNTC N/A
- Fundamental
- Price
- AENT $3.25
- BNTC $12.02
- Analyst Decision
- AENT
- BNTC Strong Buy
- Analyst Count
- AENT 0
- BNTC 7
- Target Price
- AENT N/A
- BNTC $24.43
- AVG Volume (30 Days)
- AENT 53.0K
- BNTC 59.3K
- Earning Date
- AENT 05-08-2025
- BNTC 05-12-2025
- Dividend Yield
- AENT N/A
- BNTC N/A
- EPS Growth
- AENT N/A
- BNTC N/A
- EPS
- AENT 0.13
- BNTC N/A
- Revenue
- AENT $1,070,804,000.00
- BNTC N/A
- Revenue This Year
- AENT $4.77
- BNTC N/A
- Revenue Next Year
- AENT N/A
- BNTC N/A
- P/E Ratio
- AENT $25.90
- BNTC N/A
- Revenue Growth
- AENT N/A
- BNTC N/A
- 52 Week Low
- AENT $1.10
- BNTC $4.75
- 52 Week High
- AENT $11.57
- BNTC $16.90
- Technical
- Relative Strength Index (RSI)
- AENT 37.92
- BNTC 40.15
- Support Level
- AENT $3.37
- BNTC $12.98
- Resistance Level
- AENT $4.78
- BNTC $15.08
- Average True Range (ATR)
- AENT 0.46
- BNTC 1.21
- MACD
- AENT 0.02
- BNTC -0.42
- Stochastic Oscillator
- AENT 14.04
- BNTC 8.10
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.